Medpace Reports Strong Q3 2026 Results with Increased Revenue and New $1 Billion Share Repurchase Authorization
Medpace Holdings, Inc. (MEDP) delivered robust third-quarter 2026 financial results, highlighted by a revenue increase of 8.5% year-over-year to $716 million. The company's net income grew significantly by 23.7% to $137.5 million, driven by higher interest income and improved operational efficiencies that expanded EBITDA margins to 24%. A key driver of this growth was strong project execution and a substantial increase in net new business awards, which reached $873.4 million for the quarter. The company maintains a healthy liquidity position with $705.3 million in cash and has authorized a new $1 billion share repurchase program to replace its previous authorization. While management noted that backlog cancellations reached the higher end of expected ranges due to product safety signals, they emphasized that these are not driven by customer funding issues. Looking ahead, Medpace provided optimistic full-year 2026 guidance for revenue and EPS, supported by a massive $3.17 billion ending backlog.
Tickers: $MEDP
Topics: Backlog EBITDA EPS Net Income Revenue Growth Share Repurchase
Read the full article at Motley Fool
Part of the story Freedom Financial Holdings Reports Q3 2026 Earnings Growth and Increases Share Repurchase Authorization (27 articles)